Here, we investigated TNFα, CNTF, EGF, dermorphin, dynorphin 17, substance P, somatostatin, corticotropin-releasing hormone, and the native botulinum receptor-binding domain for their ability to direct the botulinum protease into a variety of neuroendocrine tumor cells. This evidence concerns the gene CRH and neuroendocrine neoplasm.